Jevons' Disease (Adult-Onset Still's Disease) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 8 min read ✅ Medically reviewed
```html Jevons' Disease (Adult‑Onset Still’s Disease) – Complete Guide

Jevons' Disease (Adult‑Onset Still’s Disease) – A Comprehensive Medical Guide

Overview

Jevons’ disease, more commonly known today as Adult‑Onset Still’s Disease (AOSD), is a rare inflammatory disorder characterized by high fevers, joint pain, and a distinctive salmon‑pink rash. It belongs to the family of autoinflammatory syndromes, where the innate immune system becomes over‑active without a detectable external trigger such as infection.

  • Age of onset: Typically 16‑40 years, but cases have been reported in teenagers and older adults.
  • Gender distribution: Slight female predominance (≈55 % women) but overall rates are similar between sexes.
  • Prevalence: Estimated 0.16–0.4 cases per 100,000 persons worldwide [1][2]. Because the disease can mimic infections, it is often under‑diagnosed.

Symptoms

The presentation of AOSD is variable, but most patients experience a “triad” of fever, rash, and arthritis. Symptoms tend to occur in “spiking” patterns—high fever for a few days followed by a return to normal temperature.

Systemic (whole‑body) symptoms

  • Quotidian fever: Spiking > 39 °C (102 °F) usually in the late afternoon or evening, lasting 1‑3 days.
  • Salmon‑pink maculopapular rash: Non‑itchy, appears with fever, often on trunk, limbs, or peri‑nail area; may be fleeting.
  • Severe sore throat: Often described as “streptococcal‑like” and may precede fever.
  • Lymphadenopathy & splenomegaly: Enlarged lymph nodes and spleen in up to 30 % of patients.
  • Fatigue & malaise: Persistent tiredness that can limit daily activities.
  • Myalgia: Muscle aches, especially in the proximal thighs and shoulders.

Joint and musculoskeletal symptoms

  • Arthralgia or arthritis: Pain and swelling in knees, ankles, wrists, and elbows; polyarticular involvement is common.
  • Morning stiffness: Lasts > 30 minutes, reminiscent of rheumatoid arthritis.
  • Joint damage: In < 10 % of long‑standing cases, erosive arthritis may develop.

Laboratory clues

  • Markedly elevated ferritin (often > 5 000 ng/mL) with a low glycosylated fraction [3].
  • High C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
  • Neutrophilic leukocytosis (WBC > 15 000/µL).
  • Negative rheumatoid factor (RF) and anti‑CCP antibodies, helping to distinguish from rheumatoid arthritis.

Causes and Risk Factors

The exact etiology of AOSD is unknown, but current research points to a combination of genetic predisposition and abnormal innate immune activation.

Potential triggers

  • Infections: Viral (e.g., EBV, CMV, parvovirus B19) or bacterial infections may act as a “second hit” that ignites the disease in susceptible individuals.
  • Environmental exposures: Limited data suggest that exposure to certain chemicals or smoking might increase risk, but evidence is weak.

Genetic factors

  • Associations with HLA‑B17, HLA‑B35, and the IL‑1 receptor antagonist gene (IL1RN) have been reported [4].
  • Polymorphisms in cytokine genes (IL‑1β, IL‑6, IL‑18, TNF‑α) predispose to heightened inflammatory responses.

Who is at higher risk?

  • Young adults (late teens to early 40s) with a family history of autoinflammatory diseases.
  • Individuals with a recent severe viral or bacterial infection.
  • People of Northern European or Asian descent appear slightly over‑represented, though data are limited.

Diagnosis

Because AOSD mimics infections, malignancies, and other rheumatic conditions, diagnosis is essentially one of exclusion. Clinicians rely on a combination of clinical criteria, laboratory patterns, and imaging.

Diagnostic criteria

Two widely used sets are:

  1. Yamaguchi criteria (1992) – most sensitive (≈96 %). Requires ≥5 features, ≥2 of which are major (fever, rash, arthritis, neutrophilic leukocytosis) [5].
  2. Fautrel criteria (2002) – incorporates glycosylated ferritin ≤ 20 % as a major marker, offering higher specificity [6].

Laboratory work‑up

  • Complete blood count with differential.
  • Ferritin level and glycosylated fraction.
  • CRP, ESR, liver function tests (transaminases may be mildly elevated).
  • Autoantibody panel (RF, anti‑CCP, ANA) – usually negative.
  • Infectious work‑up to rule out bacterial, viral, and fungal causes (e.g., blood cultures, throat swab, viral PCR).

Imaging studies

  • Joint X‑rays: Initially normal; later may show erosions in chronic disease.
  • Ultrasound/ MRI: Detects early synovitis, effusions, and myositis.
  • Chest CT or PET‑CT: Helpful when lymphadenopathy or organomegaly raises concern for lymphoma.

Biopsy (when needed)

Skin biopsy of the rash typically shows a superficial perivascular infiltrate of neutrophils without vasculitis. Lymph node biopsies are performed only to exclude malignancy.

Treatment Options

Therapy has evolved from high‑dose steroids alone to a “step‑ladder” that incorporates disease‑modifying agents and biologics, aiming to control inflammation while minimizing medication toxicity.

First‑line: Non‑steroidal anti‑inflammatory drugs (NSAIDs)

  • Effective for mild fever and arthralgia in ~30 % of patients.
  • Use the lowest effective dose; monitor renal function and gastrointestinal risk.

Corticosteroids

  • Prednisone: 0.5–1 mg/kg daily is typical for induction; taper slowly over weeks to months.
  • High‑dose IV methylprednisolone (1 g/day × 3 days) may be required for life‑threatening systemic disease (macrophage activation syndrome, severe pulmonary involvement).
  • Long‑term steroid use carries risks (osteoporosis, diabetes, hypertension); bone‑protective agents (e.g., calcium, vitamin D, bisphosphonates) are recommended.

Conventional disease‑modifying antirheumatic drugs (cDMARDs)

  • Methotrexate (15–25 mg weekly): Most common steroid‑sparing agent; improves joint symptoms and reduces flare frequency.
  • Azathioprine, Leflunomide, or Cyclosporine: Considered when methotrexate is contraindicated.

Targeted biologic agents

Biologics block specific cytokines central to AOSD pathogenesis (IL‑1, IL‑6, TNF‑α). They are indicated for refractory disease or when rapid steroid taper is desired.

  • IL‑1 inhibitors: Anakinra (daily subcutaneous), Canakinumab (monthly). Show rapid fever and rash resolution in ≥80 % of patients [7].
  • IL‑6 receptor antagonist: Tocilizumab (IV or SC). Particularly helpful for arthritis and systemic features; improves ferritin levels.
  • TNF‑α blockers: Infliximab, Etanercept, Adalimumab – used less often but beneficial for persistent joint disease.

Adjunctive therapies

  • Colchicine: May reduce fever spikes and rash; dosage 0.6 mg 2–3 times daily.
  • Intravenous immunoglobulin (IVIG): Reserved for severe macrophage activation syndrome (MAS) or when infection cannot be excluded.

Lifestyle and supportive measures

  • Physical therapy to maintain joint range of motion.
  • Balanced diet rich in calcium and vitamin D.
  • Stress‑reduction techniques (mindfulness, yoga) as stress can exacerbate flares.

Living with Jevons' Disease (Adult‑Onset Still’s Disease)

While AOSD is chronic, many patients achieve long‑term remission with appropriate therapy. Successful daily management hinges on education, self‑monitoring, and a supportive care team.

Self‑monitoring tools

  • Fever diary: Record temperature peaks, timing, and associated symptoms.
  • Joint symptom log: Note swelling, stiffness duration, and functional limitations.
  • Laboratory trend chart: Track ferritin, CRP, and liver enzymes every 2–3 months (or as directed).

Medication adherence

  • Set daily alarms for oral meds and weekly reminders for methotrexate injections.
  • Keep a list of all medicines, doses, and side‑effects to discuss with your provider.

Physical activity

  • Low‑impact exercises (walking, swimming, stationary bike) 3–5 times/week help maintain joint mobility.
  • Avoid high‑impact activities during active flares to prevent joint injury.

Vaccinations

  • Annual influenza vaccine (inactivated) and COVID‑19 boosters are strongly recommended.
  • Live vaccines (e.g., shingles, yellow fever) should be avoided while on high‑dose steroids or biologics.

Psychosocial support

  • Join patient support groups (e.g., Still’s Disease Association) to share experiences.
  • Consider counseling if chronic pain or fatigue leads to anxiety or depression.

Prevention

Because AOSD is not caused by a preventable external factor, true primary prevention is not possible. However, the following measures may lower the risk of severe flares or complications:

  • Prompt treatment of infections—especially respiratory and streptococcal—may reduce the chance of an immune trigger.
  • Maintain a healthy weight; obesity is linked to higher inflammatory cytokine levels.
  • Avoid smoking, which can amplify IL‑1 and IL‑6 pathways.
  • Regular follow‑up with rheumatology to adjust therapy before disease progresses.

Complications

If left inadequately treated, AOSD can lead to serious organ and systemic complications:

  • Macrophage activation syndrome (MAS): Potentially fatal hyper‑inflammatory state marked by cytopenias, liver dysfunction, and coagulopathy. Occurs in 10‑15 % of patients [8].
  • Chronic erosive arthritis: Permanent joint damage in ~5 % of long‑standing cases.
  • Lung involvement: Interstitial lung disease or pleuritis in up to 20 % of patients.
  • Cardiac issues: Pericarditis, myocarditis, or coronary artery inflammation; rare but reported.
  • Hepatomegaly & elevated liver enzymes: May progress to fibrosis if inflammation persists.
  • Secondary amyloidosis: Deposition of serum amyloid A protein in kidneys, leading to proteinuria.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, extremely high fever > 40 °C (104 °F) that does not respond to antipyretics.
  • Severe chest pain, shortness of breath, or new‑onset heart palpitations.
  • Rapidly worsening abdominal pain accompanied by vomiting or jaundice.
  • Bleeding or bruising easily, or signs of low platelet count (petechiae, nosebleeds).
  • Confusion, seizures, or sudden loss of consciousness.
  • Signs of macrophage activation syndrome: persistent high fever, low blood counts, rising ferritin (> 10 000 ng/mL), and organ dysfunction.

These symptoms may indicate life‑threatening complications that require immediate intervention.

[1] Mendoza-Pinto, C. et al. Adult‑Onset Still’s Disease: Epidemiology and Clinical Features. Rheumatology International. 2021.
[2] Ravelli, A. & Martini, A. Still’s disease in adults and children. Ann Rheum Dis. 2020.
[3] Fautrel, B. et al. Ferritin and Glycosylated Ferritin as Biomarkers in AOSD. Arthritis Rheumatol. 2019.
[4] Kawashima, A. et al. HLA associations in Adult‑Onset Still’s Disease. Clin Exp Rheumatol. 2022.
[5] Yamaguchi, M. et al. Preliminary Criteria for Classification of Adult Still’s Disease. J Rheumatol. 1992.
[6] Fautrel, B. et al. New set of classification criteria for adult Still’s disease. Arthritis Rheum. 2002.
[7] Gabay, C. et al. IL‑1 blockade in Adult‑Onset Still’s Disease: A systematic review. J Clin Rheumatol. 2023.
[8] Ruscitti, P. et al. Macrophage activation syndrome in Still’s disease: clinical spectrum and therapeutic options. Lancet Rheumatology. 2021.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References